Dec 6, 2009 | PR-inside.com
Pluristem Therapeutics, Inc.-Financial Company Report - research report released
The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, dayA's sales outstanding, dayA's outstanding inventory, cash and short-term investments per share and total common shares outstanding.
Pluristem Therapeutics Presents Three Month Follow-Up Data from First ...
Nov 19, 2009 - Pluristem Therapeutics Inc. today announced that it will present three month follow-up data from the first patient to receive PLX-PAD at both the 1st Annual Conference of the German-Israeli Life Science Committee at the Life Science Center in Dsseldorf, Germany and at the DigestScience Congress in Lille, France.
Public relations, press release distribution, investor relations, SEC filing
All times in Eastern Time. HAIFA, Israel-- --Pluristem Therapeutics Inc. gab heute bekannt, dass sich in den dreimonatigen Nachbeobachtungsdaten des ersten jemals mit dem aus Plazenta gew... WEST POINT, Ga.-- --Knology, Inc.
Nov 17, 2009 - Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the ...
Pluristem Therapeutics Inc. today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass.
Customer Interaction Solutions
Short Sale Recap. Highest % Of Daily Trading Volume Short All Exchanges Combined For Thursday
BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report for Thursday, October 8th, 2009 and come to the following statistical conclusions.
News and FDA Updates for Pluristem
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Pluristem Provides Disclosure Pursuant to NASDAQ Marketplace Rule 5250
Pluristem Therapeutics Inc. today announced, that on September 23, 2009, it filed its Annual Report on Form 10-K with the SEC, which included an audit report by the company's independent registered public accounting firm containing a going concern qualification.
Pluristem Therapeutics Will Present the Phase I Study for PLX-PAD in...
Aug 11, 2009 - Pluristem Therapeutics Inc. today announced that the Phase I study for PLX-PAD in critical limb ischemia will be presented at the MSC2009 Regenerative Medicine and Adult Stem Cell Therapy conference.
Public relations, press release distribution, investor relations, SEC filing
ST. PAUL, Minn.-- --St. Jude Medical, Inc. will hold its quarterly conference call to discuss Second Quarter 2009 results on Wednesday, July 22, at 8:00 a.m. Eastern Time --Pluristem Therapeutics Inc.
Pluristem Therapeutics Announces First Patient Enrollment In Phase I...
Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials Pluristem Therapeutics Inc.
Pluristem Therapeutics Receives European Regulatory Approval For...
Main Category: Stem Cell Research Also Included In: Clinical Trials / Drug Trials ; Regulatory Affairs / Drug Approvals Article Date: 17 Jun 2009 - 0:00 PDT Pluristem Therapeutics Inc.
Pluristem Therapeutics Receives European Regulatory Approval for...
In addition, Pluristem has already received approval from the Ethics Committee and, as previously announced, the US Food & Drug Administration had cleared the Company's Investigational New Drug application to initiate a similar trial in the United States.
Pluristem Therapeutics to Present at the Second Annual Life Science...
Jun 10, 2009 - Pluristem Therapeutics Inc. , a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient cell therapy products for a variety of disorders, announced today that Mr.
Also on Topix